Baylx utilizes its proprietary technology platform to regulate the immune system, reduce inflammation, and aid in the recovery of injured and diseased tissues. Their stem cell therapies focus on autoimmune disorders and cancer, specifically using umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) technologies. Their leading candidate, BX-U001, is currently in phase 1 of clinical study for rheumatoid arthritis, while other candidates are in the preclinical stage. Founded in 2015 and based in Irvine, USA, Baylx is dedicated to translating UC-MSC technologies into clinical applications.